NRT (NicoDerm CQ) — Competitive Intelligence Brief

NRT (NicoDerm CQ) (NRT (NicoDerm CQ)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy (NRT). Area: Smoking Cessation / Addiction Medicine.

marketed Nicotine replacement therapy (NRT) Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule

Target snapshot

NRT (NicoDerm CQ) (NRT (NicoDerm CQ)) — University of California, San Francisco. NicoDerm CQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NRT (NicoDerm CQ) TARGET	NRT (NicoDerm CQ)	University of California, San Francisco	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge	Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
nicotine patch, labeled use	nicotine patch, labeled use	University of Vermont	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Placebo Tablet and Nicotine Patch	Placebo Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
bupropion + nicotine gum	bupropion + nicotine gum	University of Wisconsin, Madison	marketed	Combination smoking cessation therapy (antidepressant + nicotine replacement)	Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine)
Usual brand cigar	Usual brand cigar	Ohio State University Comprehensive Cancer Center	marketed		nicotinic acetylcholine receptors
Combination Bupropion + NRTs	Combination Bupropion + NRTs	Brentwood Biomedical Research Institute	marketed	Antidepressant + nicotine replacement combination	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy (NRT) class)

1. University of Wisconsin, Madison · 4 drugs in this class
2. Ottawa Heart Institute Research Corporation · 1 drug in this class
3. The Scripps Research Institute · 1 drug in this class
4. US Department of Veterans Affairs · 1 drug in this class
5. Chrono Therapeutics, Inc. · 1 drug in this class
6. University of Chicago · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Miami · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class